The SARS-CoV-2 neutralizing capacity of kidney transplant recipients four weeks after receiving a second dose of the BNT162b2 vaccine

COVID-19 vaccinated kidney transplant recipients (KTRs) display a lower-than-normal antibody (Ab) response towards SARS-CoV-2, indicating a reduced humoral immune response against the virus [1]. A remaining question is to which extend this translates to lower ability of KTRs to combat SARS-COV-2 [2]. This capacity can be estimated by surrogate or pseudovirus neutralization assays or, optimally, the plaque reduction neutralization test (PRNT) in which live SARS-COV-2 is challenged directly with patient blood plasma [3, 4].

Source: Kidney International - September 18, 2021 Category: Urology & Nephrology Authors: Rune M. Pedersen, Line L. Bang, Ditte S. Tornby, Helene Kierkegaard, Anna C. Nilsson, Isik S. Johansen, Claus Bistrup, Th øger G. Jensen, Ulrik S. Justesen, Thomas E. Andersen Tags: letters to the editor Source Type: research